BACKGROUND: A bilayered skin substitute composed of allogeneic keratinocytes and fibroblasts in a collagen gel has been approved by the US Food and Drug Administration for the treatment of venous and diabetic ulcers. Its mechanism of action has not been fully determined. OBJECTIVE: To determine the longevity of allogeneic fibroblasts and keratinocytes in a bilayered skin substitute in patients with venous leg ulcers. METHODS: Ten patients with venous leg ulcers were treated with a bilayered skin substitute on day 0, days 3 to 5, and weeks 1 through 3. Biopsy specimens of the grafted wound were taken. We used polymerase chain reaction analysis to determine whether allogeneic DNA was present in the biopsy specimens. RESULTS: We detected allogeneic DNA in 2 of 8 specimens at 1 month after initial grafting. Neither of the 2 patients showed persistence of allogeneic DNA at 2 months after initial grafting. CONCLUSIONS: Allogeneic cells from a bilayered skin substitute do not appear to survive permanently after grafting for treatment of venous leg ulcers. Other mechanisms of action might include cytokine release, structural support, or provision of a moist wound environment.
BACKGROUND: A bilayered skin substitute composed of allogeneic keratinocytes and fibroblasts in a collagen gel has been approved by the US Food and Drug Administration for the treatment of venous and diabetic ulcers. Its mechanism of action has not been fully determined. OBJECTIVE: To determine the longevity of allogeneic fibroblasts and keratinocytes in a bilayered skin substitute in patients with venous leg ulcers. METHODS: Ten patients with venous leg ulcers were treated with a bilayered skin substitute on day 0, days 3 to 5, and weeks 1 through 3. Biopsy specimens of the grafted wound were taken. We used polymerase chain reaction analysis to determine whether allogeneic DNA was present in the biopsy specimens. RESULTS: We detected allogeneic DNA in 2 of 8 specimens at 1 month after initial grafting. Neither of the 2 patients showed persistence of allogeneic DNA at 2 months after initial grafting. CONCLUSIONS: Allogeneic cells from a bilayered skin substitute do not appear to survive permanently after grafting for treatment of venous leg ulcers. Other mechanisms of action might include cytokine release, structural support, or provision of a moist wound environment.
Authors: Andrea Piccin; Angela M Di Pierro; Lucia Canzian; Marco Primerano; Daisy Corvetta; Giovanni Negri; Guido Mazzoleni; Günther Gastl; Michael Steurer; Ivo Gentilini; Klaus Eisendle; Fabrizio Fontanella Journal: Blood Transfus Date: 2016-07-25 Impact factor: 3.443
Authors: John M Centanni; Joely A Straseski; April Wicks; Jacquelyn A Hank; Cathy A Rasmussen; Mary A Lokuta; Michael J Schurr; Kevin N Foster; Lee D Faucher; Daniel M Caruso; Allen R Comer; B Lynn Allen-Hoffmann Journal: Ann Surg Date: 2011-04 Impact factor: 12.969
Authors: Vincent Falanga; Roslyn Rivkah Isseroff; Athena M Soulika; Marco Romanelli; David Margolis; Suzanne Kapp; Mark Granick; Keith Harding Journal: Nat Rev Dis Primers Date: 2022-07-21 Impact factor: 65.038
Authors: Cathy A Rasmussen; Angela L Gibson; Sandy J Schlosser; Michael J Schurr; B Lynn Allen-Hoffmann Journal: Ann Surg Date: 2010-02 Impact factor: 12.969